PHVS

Pharvaris N.v.

A biopharmaceutical company developing oral pills for hereditary angioedema, a rare genetic disorder that causes sudden, painful swelling attacks. Its lead drug candidate, deucrictibant, aims to offer patients a pill instead of the injections they currently use. The company was founded in 2015 in Leiden, the Netherlands, when chemist Jochen Knolle—inventor of the injectable HAE drug icatibant—teamed up with colleagues to create an oral version of the same idea. The name blends "pharma" with a made-up suffix.

No proxy statement recorded.